Browsing Tag
Ionis Pharmaceuticals
10 posts
Kardigan’s tonlamarsen data put acute severe hypertension into sharper commercial focus
Kardigan’s tonlamarsen Phase 2 data showed blood pressure promise despite mixed endpoints. Read what it means for acute severe hypertension next.
Can zilganersen become the first disease-modifying therapy for Alexander disease?
Ionis wins FDA breakthrough therapy status for zilganersen in Alexander disease. Find out what this means for rare neurology drug development.
Ionis and SOBI’s olezarsen cuts pancreatitis risk by 85% in sHTG phase 3 trials
Olezarsen showed 85% reduction in acute pancreatitis for severe hypertriglyceridemia. See what this means for Sobi, Ionis, and upcoming EMA and FDA filings.
Ionis Pharmaceuticals’ olezarsen reduces pancreatitis by 85% in late-stage sHTG trial
Ionis Pharmaceuticals reports 85% drop in pancreatitis with olezarsen in Phase 3 sHTG trial. Find out what the AHA late-breaker results could mean for FDA approval.
Biotech rivals clash as Arrowhead sues Ionis over RNA-based triglyceride therapy
Arrowhead sues Ionis over APOC3 patent dispute as plozasiran nears FDA approval. Discover what’s at stake in this RNA-based biotech rivalry.
Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE
In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S.…
GSK advances in Hepatitis B cure with FDA’s fast track for bepirovirsen
In a significant development for the treatment of chronic hepatitis B (CHB), GSK plc (LSE/NYSE: GSK) has announced…
AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN
In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration…
Ionis Pharmaceuticals begins donidalorsen phase 3 trial in hereditary angioedema
Ionis Pharmaceuticals, a US-based developer of RNA-targeted therapies, has launched the OASIS-HAE phase 3 clinical trial for donidalorsen…
Ionis Pharmaceuticals to take full ownership of Akcea Therapeutics
Ionis Pharmaceuticals is set to take full ownership of Akcea Therapeutics by acquiring the remaining stake of around…